Melanotan II: Compound Profile

Melanotan II (MT-II) is one of the most misunderstood peptides in circulation. It is a genuinely interesting molecule of receptor pharmacology — a cyclic, protease- resistant α-MSH analog roughly a thousand-fold more potent than its endogenous parent — and it is the originator molecule of an entire branch of drug development that produced two FDA-approved descendants. It is also a peptide that was never carried through Phase 3 for any indication in its own right, that the FDA, MHRA, and TGA have all issued public warnings against, and that the case-report literature implicates in eruptive nevi, biopsy-proven melanoma, PRES, rhabdomyolysis, and priapism.

Both of those things are true at once. The science is real; the unregulated consumption pattern is dangerous; and the two have been conflated in almost every popular treatment of the compound. This profile attempts to keep them separate: what the molecule is, what was learned in the small early human trials, what the FDA- approved spinoff drugs settled, and what the safety signal in the unregulated market actually shows.

At a glance

Sequence and structural details derive from the original Al-Obeidi 1989 medicinal- chemistry paper^[1]and the Hadley & Dorr 2006 historical review^[9].

What Melanotan II is

Melanotan II is a synthetic cyclic heptapeptide developed at the University of Arizona in the late 1980s by a collaboration between Mac Hadley (Department of Cell Biology), Victor Hruby (Department of Chemistry), and Robert Dorr (College of Pharmacy). The starting point was the active core of α-MSH — the residues 4–10 of the native tridecapeptide — with two key modifications: a cyclic lactam between Asp² and Lys⁷ and a D-stereochemistry substitution at position 4 (D-Phe). The cyclization rigidifies the molecule into the bioactive conformation and protects against amino-peptidase cleavage; the D-Phe substitution further slows protease attack at position 4^[1][2].

The result is a compound that is both substantially more potent than α-MSH on melanogenesis assays and substantially longer-acting in vivo. Where native α-MSH is cleared on the order of minutes, MT-II acts on the order of hours and is active across the entire melanocortin receptor family rather than selectively at MC1R.

That receptor non-selectivity is critical. The melanocortin family comprises five receptors with distinct tissue distributions: MC1R on melanocytes (pigmentation), MC2Ron adrenal cortex (ACTH receptor — not meaningfully engaged by MT-II), MC3R and MC4R in the central nervous system (energy balance, appetite, sexual function), andMC5Ron exocrine glands. MT-II engages all of these except MC2R, which is why its in-vivo effects extend well beyond pigmentation to include appetite suppression, spontaneous penile erection, nausea, and blood-pressure / heart-rate changes — effects that figure prominently in both the original Phase I trials and the contemporary safety case-report literature.

Mechanism

Each of the four melanocortin receptors engaged by MT-II is a Gαs-coupled GPCR. Receptor binding activates adenylyl cyclase, increases intracellular cAMP, and activates protein kinase A. At MC1R on melanocytes, PKA phosphorylates CREB, upregulates MITF (the master transcription factor of melanogenesis), and increases tyrosinase expression — producing a shift in melanin synthesis toward eumelanin. At MC4R in the hypothalamus, the same cAMP / PKA cascade modulates feeding behavior and contributes to penile erection through downstream effects on oxytocinergic and dopaminergic pathways^[8]. At MC3R, the contribution to energy balance is more debated but appears to involve auto- regulation of POMC neurons.

Evidence map

The MT-II evidence base is concentrated in a handful of small academic Phase I trials from the early- to mid-1990s, plus a much larger body of in-vitro receptor pharmacology and a sizable case-report literature from the unregulated market. No Phase 2 or Phase 3 program for MT-II itself was completed. The downstream programs that werecompleted — bremelanotide and afamelanotide — used different molecules and are summarized in the section that follows.

Tanning and pigmentation — Dorr 1996 and the early human trials

The first published human evidence of UV-independent melanocortin-induced tanning came from the Arizona group themselves. Levine and colleagues, working with Hadley, Hruby, and Dorr, reported in JAMA in 1991 that subcutaneous administration of a potent synthetic melanotropin induced skin tanning in healthy volunteers^[3]. That study used the linear MT-I analog, not the cyclic MT-II.

Five years later, Dorr and colleagues published the pilot Phase I trial of MT-II itself in Life Sciences^[4]. The trial enrolled a small group of healthy male volunteers receiving subcutaneous MT-II at escalating doses. Dose-dependent skin darkening was observed, consistent with the in-vitro MC1R potency. The adverse-event profile in that trial — nausea, facial flushing, spontaneous penile erection — established the receptor non-selectivity signature that has defined MT-II's clinical pharmacology ever since.

No larger controlled MT-II tanning trial was ever published. The development pathway for an FDA-approved melanocortin tanning agent shifted to the more MC1R- selective linear MT-I (afamelanotide), and ultimately to its narrow approval for erythropoietic protoporphyria rather than cosmetic pigmentation^[18].

Erectile function and the bremelanotide branch

Wessells and colleagues at the University of Arizona reported in 1998 that subcutaneous MT-II initiated erections in men with psychogenic erectile dysfunction in a double-blind placebo-controlled crossover design^[6]. A 2000 follow-up extended the observation to men with organic erectile dysfunction^[7]. King and colleagues' 2007 review^[8] synthesizes the mechanism: MC4R agonism in the paraventricular nucleus of the hypothalamus modulates oxytocinergic and dopaminergic signaling, which in turn engages the spinal erection generator. The effect is centrally mediated, in contrast to the peripheral vasodilation produced by PDE5 inhibitors.

These MT-II findings became the rationale for developing bremelanotide (PT-141), a metabolite-derived analog with improved selectivity for MC3R / MC4R. Bremelanotide advanced through Phase 3 trials in hypoactive sexual desire disorder (HSDD) in premenopausal women^[16] and was FDA- approved in June 2019 as Vyleesi^[17]. The MT-II to PT-141 development arc is the cleanest example of the original University of Arizona program producing an approved therapeutic — though the approval is for an indication and a population distinct from the original MT-II observations.

Appetite, body weight, and MC4R

Central MC4R agonism is a well-established appetite-suppression mechanism. The clinical validation of this pathway came not from MT-II but from setmelanotide (Imcivree), a different MC4R agonist FDA-approved in 2020 for obesity in rare monogenic disorders of the POMC / leptin-melanocortin pathway. No controlled human weight-loss trial of MT-II has been published, and the centrally-mediated nausea associated with MT-II would in practice be dose- limiting before any sustained weight-loss program could be conducted. The appetite-suppression component of MT-II's pharmacology is best understood as a receptor-pharmacology fact, not a clinical claim.

Safety profile

The MT-II safety record reflects two distinct settings: the small academic Phase I trials of the 1990s, and the much larger volume of unregulated self-administration from roughly 2005 onward. Both contribute meaningful information; neither substitutes for a controlled Phase 2/3 program.

• Nausea and facial flushing— the most common adverse events in the early trials and in subsequent case series. Dose-limiting in Dorr 1996^[4].
• Spontaneous penile erection / priapism— on-target MC4R effect; observed in the early trials, dose-limiting in some participants, and implicated in priapism case reports in the unregulated market.
• Eruptive nevi and dysplastic mole change— documented in multiple case reports and case series. Cardones & Grichnik (Arch Dermatol 2009)^[11] described α-MSH-induced eruptive nevi; Langan and colleagues (BMJ 2009)^[10] documented mole change in MT-II users. The Habbema 2017 review^[13] synthesizes the dermatologic case literature.
• Melanoma in temporal association with use— Paurobally and colleagues (BJD 2011)^[12] reported a biopsy-proven melanoma in a young MT-II user. Subsequent case reports have added to this signal. Temporal association does not establish causation; the biological plausibility (melanocyte proliferation in the setting of pre-existing dysplastic potential) is real.
• Posterior reversible encephalopathy syndrome (PRES)— Devoto and colleagues (Clinical Toxicology 2017)^[15] reported a case following subcutaneous MT-II self-administration, consistent with the known blood-pressure and cerebrovascular pharmacology of the melanocortin family.
• Rhabdomyolysis— case reports exist in the dermatology and emergency-medicine literature; mechanism is not fully elucidated.
• Cardiovascular signal— transient increases in blood pressure and heart rate observed in early trials, consistent with melanocortin autonomic effects.
• Counterfeit and contamination risk— the unregulated market is characterized by uncertain provenance, no analytical certification, and reports of products containing non-MT-II material or under-dosed product. This adds a contamination dimension to the safety profile that is separate from the pharmacology of MT-II itself.

Afamelanotide and bremelanotide — the approved descendants

Two molecules derived from the Arizona melanocortin program received FDA approval:

• Afamelanotide (Scenesse)— a linear tridecapeptide ([Nle⁴, D-Phe⁷]-α-MSH) with greater MC1R selectivity than MT-II. Developed by Clinuvel Pharmaceuticals; approved by the FDA in October 2019 for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare metabolic disorder^[18]. Delivered as a subcutaneous implant. EMA approval in 2014. Not approved for cosmetic tanning in any jurisdiction.
• Bremelanotide (Vyleesi, PT-141)— an MT-II metabolite- derived analog. Developed by Palatin Technologies and AMAG Pharmaceuticals; approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women^[17]. Delivered as a subcutaneous autoinjector. Originally developed for erectile dysfunction; intranasal program was discontinued due to blood-pressure findings.

Both approved molecules went through Phase 3 outcome trials, FDA review, and post-marketing surveillance. MT-II itself did not. Treating MT-II as a "consumer version" of either approved drug — a framing the unregulated market often encourages — misreads the regulatory history: MT-II was the originator molecule, both Scenesse and Vyleesi were the molecules that were carried through development because MT-II was not.

Regulatory status and public-health warnings

Multiple regulatory authorities have issued explicit public warnings against human use of MT-II:

• United Kingdom (MHRA)— classified MT-II and MT-I as unlicensed medicinal products and issued repeated public warnings, beginning in 2008 and reiterated through 2015^[19]. Vendors marketing for human use have been subject to enforcement action.
• Australia (TGA)— classified MT-II as a Schedule 4 prescription-only substance, with explicit safety advisories warning against unsupervised use^[20].
• United States (FDA)— issued multiple warning letters and enforcement actions against vendors marketing MT-II for human cosmetic or tanning use. No FDA approval exists for MT-II for any indication.
• Netherlands, Norway, Sweden, Denmark— national medicines authorities have published similar public warnings, summarized in the Habbema 2017 review^[13].

Brennan, Wells, and Van Hout's 2017 study^[14] of injecting use of image and performance-enhancing drugs documents the gap between the regulatory picture and consumer practice: an active online culture of MT-II self- administration that operates almost entirely outside the regulated medical system. This is the population in which most of the recent dermatologic and emergency-medicine case reports originate.

Development timeline

Limitations of the evidence base

• No Phase 2 or Phase 3 program for MT-II itself. The published human evidence is concentrated in small academic Phase I trials from the 1990s. Statements about long-term efficacy or risk in MT-II specifically are extrapolations from those trials plus the unregulated case-report literature.
• The approved spinoff drugs are not MT-II. Afamelanotide is a different sequence with different receptor selectivity; bremelanotide is a different (smaller) sequence with different receptor selectivity. Evidence generated about Scenesse or Vyleesi cannot be directly transferred to MT-II.
• Case-report literature cannot establish causation. Temporal association between MT-II use and eruptive nevi, melanoma, PRES, or rhabdomyolysis is documented and reproducible across multiple authors and countries. The magnitude of the causal effect cannot be quantified from case reports alone; that would require a controlled trial.
• Unregulated supply contaminates the safety signal. Adverse events in the unregulated market may reflect MT-II pharmacology, MT-II impurities, mis-identified compound, dosing errors, or unsterile injection technique. Distinguishing these contributions is not possible from the existing literature.
• No long-term outcome data of any kind. Chronic-use safety, long-term melanoma incidence, and reproductive / developmental endpoints have not been studied in any controlled human trial.

Reconstitution & handling

MT-II ships from PepMax as a lyophilized powder. Reconstitute with bacteriostatic water for injection (0.9% benzyl alcohol) for multi-day storage in solution, or sterile water for injection when the bacteriostatic preservative is undesirable for a given research design. Add the diluent slowly down the inside wall of the vial; do not direct the stream onto the lyophilized cake. Swirl gently to dissolve; do not vortex or shake. Store the lyophilized vial at −20 °C or below, protected from light and moisture; once reconstituted, refrigerate (2–8 °C) and use within the protocol-defined window. Avoid repeated freeze-thaw cycles.

For background on the analytical numbers on a peptide’s certificate of analysis — HPLC purity, mass-spectrometric identity confirmation, water content — see our companion methods articles on what ≥99% purity actually means and how we verify peptide purity.

Further reading

The bibliography below points to the primary papers and regulatory documents referenced in this profile. The Al-Obeidi 1989 paper^[1] is the original medicinal-chemistry account of the cyclic-lactam scaffold; Dorr 1996^[4] is the only published MT-II Phase I trial; Wessells 1998^[6] is the highest-yield primary reading for the erectile- function pharmacology and the bremelanotide development substrate; Habbema 2017^[13] is the most comprehensive review of the unregulated-market safety literature.